98%
921
2 minutes
20
Objectives: This study aimed to elucidate the mechanisms of chiropractic care using resting electroencephalography (EEG), somatosensory evoked potentials (SEPs), clinical health assessments (Fitbit), and Patient-reported Outcomes Measurement Information System (PROMIS-29).
Methods: Seventy-six people with chronic low back pain (mean age ± SD: 45 ± 11 years, 33 female) were randomised into control ( = 38) and chiropractic ( = 38) groups. EEG and SEPs were collected pre and post the first intervention and post 4 weeks of intervention. PROMIS-29 was measured pre and post 4 weeks. Fitbit data were recorded continuously.
Results: Spectral analysis of resting EEG showed a significant increase in Theta, Alpha and Beta, and a significant decrease in Delta power in the chiropractic group post intervention. Source localisation revealed a significant increase in Alpha activity within the Default Mode Network (DMN) post intervention and post 4 weeks. A significant decrease in N30 SEP peak amplitude post intervention and post 4 weeks was found in the chiropractic group. Source localisation demonstrated significant changes in Alpha and Beta power within the DMN post-intervention and post 4 weeks. Significant improvements in light sleep stage were observed in the chiropractic group along with enhanced overall quality of life post 4 weeks, including significant reductions in anxiety, depression, fatigue, and pain.
Conclusions: These findings indicate that many health benefits of chiropractic care are due to altered brain activity.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11592102 | PMC |
http://dx.doi.org/10.3390/brainsci14111124 | DOI Listing |
Arch Phys Med Rehabil
September 2025
Department of Physical Therapy, University of Delaware, Newark, DE, USA; Biomechanics and Movement Science Program, University of Delaware, Newark, DE, USA. Electronic address:
Objective: To examine if exercise intensity, quantified as heart rate or training speed, predicts walking outcomes in people with chronic stroke.
Design: This is a secondary analysis from a larger randomized clinical trial ("PROWALKS"; NIH1R01HD086362).
Setting: Four, outpatient rehabilitation clinics.
Contemp Clin Trials
September 2025
Weill Cornell Medicine Center for Global Health, New York, NY, USA.
Introduction: Preclinical and clinical study data show that combining bedaquiline (B or BDQ), moxifloxacin (M), and pyrazinamide (Z), known as BMZ, has potent antimicrobial activity that might shorten treatment duration for drug-susceptible pulmonary tuberculosis.
Methods/design: We describe the design of Tuberculosis Trials Consortium (TBTC) Study 38/CRUSH-TB (NCT05766267), an open-label multicenter international randomized controlled phase 2C trial that compares two four-month regimens, BMZ plus rifabutin (Rb) (2BMZRb/2BMRb) or BMZ plus delamanid (D or DLM) (2BMZD/2BMD), with standard 6-months isoniazid, rifampin, pyrazinamide, and ethambutol (HRZE). All drugs are administered seven days per week, under direct observation, at least five days per week.
Lancet HIV
September 2025
Department of Clinical Research, London School of Hygiene and Tropical Medicine, London, UK; Botswana Harvard Health Partnership, Gaborone, Botswana.
Background: HIV-associated cryptococcal meningitis case fatality remains greater than 25%. Co-prevalent infections might contribute to poor outcomes. We aimed to ascertain the prevalence and the clinical significance of Epstein-Barr virus (EBV) and cytomegalovirus co-infections in patients with cryptococcal meningitis to guide potential therapeutic interventions.
View Article and Find Full Text PDFLancet Rheumatol
September 2025
Bristol Royal Hospital for Children and Translational Health Sciences, Bristol, UK. Electronic address:
Background: Baricitinib has previously been shown to improve clinical response in patients with juvenile idiopathic arthritis (JIA) in the JUVE-BASIS trial. In this post-hoc analysis we aimed to identify whether pharmacodynamic changes in serum biomarkers in response to baricitinib treatment could help reaffirm the clinical utility of baricitinib in patients with JIA.
Methods: JUVE-BASIS was a randomised, double-blind, placebo-controlled, withdrawal, efficacy, safety, phase 3 trial, done in 75 centres in 20 countries.
Urol J
September 2025
Isfahan Kidney Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Purpose: Men with lower urinary tract symptoms (LUTS) from benign prostatic hyperplasia (BPH) often experience erectile dysfunction (ED). While transurethral resection of the prostate (TURP) can improve ED, new-onset ED remains a concern. This study compares monopolar (M-TURP) and bipolar (B-TURP) techniques, with a subgroup analysis based on phosphodiesterase-5 inhibitor (PDE5i) use.
View Article and Find Full Text PDF